Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versus placebo in patients with high-risk MIUC after radical surgery demonstrated that adjuvant nivolumab improved disease-free survival (DFS) versus placebo. We report results with 5-year minimum follow-up including exploratory analyses of circulating tumor DNA (ctDNA).
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274☆
Annals of Oncology | | M.D. Galsky, J.E. Gschwend, M.I. Milowsky, M. Schenker, B.P. Valderrama, Y. Tomita, A. Bamias, T. Lebret, S.F. Shariat, S.H. Park, M. Agerbaek, G. Jha, F. Stenner, D. Ye, F. Giudici, J. Connors, S. Gupta, A. Chhibber, J. Zhang, D.F. Bajorin, J.A. Witjes
Topics: bladder-cancer, cervical-cancer, immunotherapy, targeted-therapy, clinical-trials, new-technology